The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Radiation and androgen deprivation therapy with or without docetaxel in the management of non-metastatic unfavorable-risk prostate cancer: A prospective randomized trial.
 
Anthony Victor D'Amico
No Relationships to Disclose
 
Wanling Xie
No Relationships to Disclose
 
Elizabeth McMahon
No Relationships to Disclose
 
Marian Loffredo
No Relationships to Disclose
 
Shana Medeiros
No Relationships to Disclose
 
David John Joseph
No Relationships to Disclose
 
James William Denham
No Relationships to Disclose
 
David S Lamb
No Relationships to Disclose
 
Parvesh Kumar
No Relationships to Disclose
 
Glenn Bubley
No Relationships to Disclose
 
Molly A. Sullivan
Employment - Elektrofi (I); Moderna Therapeutics (I)
 
Richard Hellwig
No Relationships to Disclose
 
Juan Carlos Vera
No Relationships to Disclose
 
Rolf Freter
No Relationships to Disclose
 
W. Jeffrey Baker
No Relationships to Disclose
 
Jeffrey Y.C. Wong
Research Funding - Accuray (Inst); Accuray (Inst); Varian Medical Systems (Inst)
 
Andrew A. Renshaw
No Relationships to Disclose
 
Philip W. Kantoff
Leadership - Context Therapeutics
Stock and Other Ownership Interests - Context Therapeutics; Druggablity Technologies; Placon; Seer
Consulting or Advisory Role - Bavarian Nordic; Context Therapeutics; Druggablity Technologies; GE Healthcare; Genentech/Roche; Janssen; Merck; OncoCellMDX; Progenity; Seer; Tarveda Therapeutics
Patents, Royalties, Other Intellectual Property - Chromosome Copy Number Gain as a Biomarker of Urothelial Carcinoma Lethality; Composition and Methods for Screening and Diagnosis of Prostate Cancer; Drug Combinations to Treat Cancer; Method for Predicting the Risk of Prostate Cancer Morbidity and Mortality; Methods and Kits for Determining Sensitivity to Cancer Treatment; Methods for Predicting Likelihood of Responding to Treatment; Predicting and Treating Prostate Cancer; Somatic ERCC2 Mutations Correlate with Cisplatin sensitivity in muscle-invasive Urothelial Carcinoma (Patent); Up-to-Date Royalties; Wolters Kluwer Royalties